8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2013 / Open-label clinical trial
Forty-three women with newly diagnosed operable breast cancer took 2 grams of limonene daily for 2 to 6 weeks before surgical resection. Limonene preferentially concentrated in breast tissue, reaching a mean level of 41.3 µg/g, and led to a 22% reduction in tumor cyclin D1 expression (p = 0.002). Circulating IGF-I increased slightly, while tissue Ki67, cleaved caspase-3, leptin, adiponectin, and IL-6 showed no significant alterations.
Miller JA, Lang JE, Ley M, et al. Cancer Prev Res (Phila), 2013. PMID 23554130
2013 / Phase I dose-escalation clinical trial
Five cohorts of three patients with advanced solid tumors received intravenous ascorbic acid at 1 g/min for 4 consecutive days per week for 4 weeks, starting at 30 g/m² with 20 g/m² dose escalations. Ascorbic acid was eliminated by first-order kinetics with a half-life of 2.0 ± 0.6 h and clearance of 21 ± 5 dL/h m². Cmax and AUC increased with dose up to 70 g/m² (reaching 49 mM and 220 h mM, respectively). All doses were well tolerated, but no patient demonstrated an objective antitumor response.
Stephenson CM, Levin RD, Spector T, et al. Cancer Chemother Pharmacol, 2013. PMID 23670640
2013 / Single-blind placebo-controlled crossover trial
In a 3-month trial, 15 postmenopausal women took 5 g daily of placebo for 4 weeks, seaweed (Undaria) for 4 weeks, and placebo for another 4 weeks. Urinary creatinine-standardized uPAR decreased significantly during seaweed intake (placebo 1: 1.5 [95% CI, 0.9-2.1]; seaweed: 0.9 [95% CI, 0.6-1.1]; placebo 2: 1.7 [95% CI, 1.2-2.2]; p = 0.01). A urinary protein (m/z 9,776) showed a similar reversible decrease, while a serum protein (m/z 8,928) reversibly increased.
Teas J, Vena S, Cone DL, et al. J Appl Phycol, 2013. PMID 23678231
2013 / Randomized controlled trial
In the Women's Health Initiative Dietary Modification trial, 48,835 postmenopausal women were randomized to a low-fat dietary pattern intervention (n = 19,541) or a comparison group (n = 29,294) with a target of decreasing fat to 20% or less of calories and increasing vegetables, fruits, and grains. Over 8.1 years of follow-up, the intervention did not significantly affect overall incidence of NMSC (HR 0.98; 95% CI, 0.92-1.04) or melanoma (HR 1.04; 95% CI, 0.82-1.32). However, a significant interaction was observed between baseline fat intake and group assignment for melanoma risk (Pinteraction = 0.006), showing increased risk with the intervention among women with higher baseline fat intake (HR 1.48; 95% CI, 1.06-2.07) and a trend toward reduced risk among those with lower baseline fat intake (HR 0.72; 95% CI, 0.50-1.02).
Gamba CS, Stefanick ML, Shikany JM, et al. Cancer Epidemiol Biomarkers Prev, 2013. PMID 23697610
2013 / Randomized controlled trial
A multicenter trial randomized 177 men at high risk of prostate cancer recurrence to receive daily powder with 20 g of soy protein isolate or calcium caseinate for up to 2 years. The trial was halted early for futility after an interim analysis of 159 evaluable men. Biochemical recurrence developed in 27.2% of the soy group and 29.5% of the placebo group, showing no significant difference (hazard ratio 0.96; 95% CI, 0.53-1.72; P = .89).
Bosland MC, Kato I, Zeleniuch-Jacquotte A, et al. JAMA, 2013. PMID 23839751
2013 / Secondary analysis of a randomized controlled trial
An analysis of 7,216 participants in the PREDIMED trial evaluated nut intake over a median follow-up of 4.8 years. Compared with non-consumers, individuals consuming more than three servings of nuts weekly had a 39% lower risk of total mortality (HR 0.61; 95% CI 0.45 to 0.83). Nut consumption was also linked to reduced risk of cardiovascular and cancer death, with the lowest overall mortality observed among nut group participants consuming this amount.
Guasch-Ferré M, Bulló M, Martínez-González MÁ, et al. BMC Med, 2013. PMID 23866098
2013 / Randomized controlled trial
Eighty-six men awaiting prostatectomy were randomized to consume 80 mg daily of isoflavones or a placebo for up to six weeks. Microarray analysis revealed down-regulation of 12 cell cycle control genes and 9 apoptosis genes in tumor tissue from the supplement arm. However, shifts in circulating estrogens, androgens, PSA, and total cholesterol showed no statistically significant differences between groups.
Hamilton-Reeves JM, Banerjee S, Banerjee SK, et al. PLoS One, 2013. PMID 23874588
2013 / Randomized controlled trial
Subjects were randomly assigned to consume 400 g standard broccoli, 400 g high-glucoraphanin (HG) broccoli, or 400 g peas each week for 12 weeks. No significant differences in the effects of the diets on biomarkers of CVD risk were detected. However, univariate analysis showed significant effects of sex (P < 0.001), PAPOLG genotype (P < 0.001), and PAPOLG genotype × diet (P < 0.001) on plasma metabolic profiles. In the HG broccoli arm, the intervention reduced variation between the two PAPOLG genotypes in lipid and amino acid metabolites, tricarboxylic acid (TCA) cycle intermediates, and acylcarnitines.
Armah CN, Traka MH, Dainty JR, et al. Am J Clin Nutr, 2013. PMID 23964055
2013 / Randomized controlled trial
Seventy men awaiting radical prostatectomy were randomized to take two pomegranate extract tablets or placebo daily for up to four weeks. Pomegranate extract was linked to an 8-hydroxy-2'-deoxyguanosine reduction of 16% in benign tissue, which did not reach statistical significance (P = 0.095). Urolithin A accumulated in prostate tissue in 21 of 33 treated patients versus 12 of 35 controls (P = 0.031), while markers such as Ki67, NF-kappaB, and PSA were unaltered.
Freedland SJ, Carducci M, Kroeger N, et al. Cancer Prev Res (Phila), 2013. PMID 23985577
2013 / Follow-up comparative pilot study
This pilot study compared 10 men undergoing a 5-year comprehensive lifestyle intervention (diet, activity, stress management, social support) with 25 external controls on active surveillance. At 5 years, relative telomere length increased from baseline by a median of 0.06 T/S units (IQR -0.05 to 0.11) in the intervention group and decreased by -0.03 T/S units (-0.05 to 0.03) in controls (p=0.03). Combined data showed each percentage point increase in lifestyle adherence score was associated with a 0.07 increase in T/S units (95% CI 0.02-0.12, p=0.005). Telomerase activity decreased in both groups (intervention: -0.25 units; controls: -1.08 units; p=0.64) and did not significantly associate with lifestyle adherence.
Ornish D, Lin J, Chan JM, et al. Lancet Oncol, 2013. PMID 24051140
2013 / Randomized crossover trial
In a randomized crossover trial, 76 participants consumed 25 g/d of blue lupin, white lupin, or soya fibre, compared with citrus fibre, for two weeks each. Supplementation with lupin fibres increased fecal dry matter and weight, enhanced short-chain fatty acids, and all legume fibres reduced fecal total and secondary bile acids by 16% to 24%. Blood lipids were not influenced by any of the fiber interventions.
Fechner A, Fenske K, Jahreis G Nutr J, 2013. PMID 24060277
2013 / Phase IIb double-blind randomized placebo-controlled trial
In a phase IIb trial, 98 patients with advanced prostate cancer received either 500 ml of pomegranate juice or 500 ml of placebo beverage daily for 4 weeks, followed by 250 ml of pomegranate juice daily for all patients for another 4 weeks. Adherence was high, with 94 patients (96%) completing the first period and 87 patients (89%) completing both periods. No differences were detected between the two groups regarding PSA kinetics and pain scores, and no grade 3 or higher toxicities occurred.
Stenner-Liewen F, Liewen H, Cathomas R, et al. J Cancer, 2013. PMID 24069070
2012 / Dietary intervention study
Researchers evaluated the impact of a 7-day dietary red meat intervention in human subjects on endogenous N-nitroso compound (NOC) formation and fecal water genotoxicity relative to colonic transcriptomic changes. The intervention did not alter fecal NOC excretion, but fecal water genotoxicity increased significantly after red meat consumption. Colonic inflammation from inflammatory bowel disease did not impact fecal NOC excretion or genotoxicity. Transcriptomic analyses showed genes correlating with higher fecal water genotoxicity were involved in DNA damage repair, cell cycle, apoptosis, WNT signaling, and nucleosome remodeling pathways.
Hebels DG, Sveje KM, de Kok MC, et al. Food Chem Toxicol, 2012. PMID 22019696
2012 / Randomized controlled trial
A randomized trial tested daily polyphenon E containing 800 mg epigallocatechin gallate against placebo for 3 to 6 weeks before radical prostatectomy in prostate cancer patients. Polyphenol accumulation in surgical prostate tissue remained low or undetectable following supplementation. Treatment produced favorable but non-significant shifts in prostate-specific antigen, insulin-like growth factor axis markers, leukocyte DNA damage, Gleason scores, cell proliferation, apoptosis, and angiogenesis.
Nguyen MM, Ahmann FR, Nagle RB, et al. Cancer Prev Res (Phila), 2012. PMID 22044694
2012 / Randomized noncomparative phase II trial
Seventy-five patients with dysplastic esophageal lesions were assigned to consume 30 g/d or 60 g/d of freeze-dried strawberry powder for six months. The 30 g/d intake showed no significant histological effect. In contrast, 60 g/d reduced lesion grade in 29 of 36 evaluated individuals (80.6%, P < 0.0001) and significantly lowered tissue markers including iNOS, COX-2, pNFkB-p65, pS6, and Ki-67.
Chen T, Yan F, Qian J, et al. Cancer Prev Res (Phila), 2012. PMID 22135048
2012 / Crossover trial
In a crossover study, 36 women were assigned to consume 8 ounces (237 mL) of red wine daily and white wine daily for 1 month each in alternate orders. Blood collected twice during the menstrual cycle showed that red wine resulted in higher free testosterone (mean difference 0.64 pg/mL [0.2 SE], p=0.009), lower SHBG (mean difference -5.0 nmol/L [1.9 SE], p=0.007), and significantly higher LH (mean difference 2.3 mIU/mL [1.3 SE], p=0.027) compared with white wine. Estradiol levels were lower with red wine versus white wine, but this was not statistically significant, and FSH levels did not differ significantly.
Shufelt C, Merz CN, Yang Y, et al. J Womens Health (Larchmt), 2012. PMID 22150098
2012 / Masked factorial randomized placebo-controlled trial
Participants were tracked for 14.7 years following interventions in the Shandong Intervention Trial. Long-term supplementation with garlic or vitamins (C, E, and selenium) was linked to non-statistically significant decreases in gastric cancer incidence and mortality. However, vitamin supplementation significantly lowered combined deaths from gastric or esophageal cancer (hazard ratio = 0.51, 95% CI = 0.30 to 0.87; P = .014).
Ma JL, Zhang L, Brown LM, et al. J Natl Cancer Inst, 2012. PMID 22271764
2012 / Phase I dose-escalation trial
In a dose-escalation trial of 14 patients with stage IV pancreatic cancer, nine completed an eight-week cycle of thrice-weekly intravenous ascorbic acid alongside gemcitabine and erlotinib. The trial recorded 15 non-serious and eight serious adverse events, all deemed related to disease progression or chemotherapy. RECIST evaluation showed stable disease in seven participants and progressive disease in two, indicating no added toxicity from ascorbic acid.
Monti DA, Mitchell E, Bazzan AJ, et al. PLoS One, 2012. PMID 22272248
2012 / Randomized double-blind crossover trial and open-label extension
In a randomized, double-blind crossover study with 36 patients, participants received a 4g dose of curcumin or placebo for 3 months before crossing over, followed by an optional 8g open-label extension. Curcumin treatment decreased the free light-chain ratio and reduced the difference between clonal and nonclonal light chains. Urine DPYD, representing bone resorption, decreased with curcumin but rose with placebo, while serum creatinine tended to drop.
Golombick T, Diamond TH, Manoharan A, et al. Am J Hematol, 2012. PMID 22473809
2012 / Randomized controlled trial
A randomized trial assigned 36 men with recurrent prostate cancer to waitlist control or an 11-week dietary and mindfulness program. Participants in the intervention significantly decreased their animal-to-vegetable protein ratio at 3 months (P=0.01) and maintained it at 6 months (P=0.049). Practice of mindfulness correlated with both the initial adoption and the maintenance of this dietary shift.
Carmody JF, Olendzki BC, Merriam PA, et al. J Acad Nutr Diet, 2012. PMID 22853988
2012 / Intervention trial with microdialysis and ex vivo biopsy culture
Researchers performed microdialysis in healthy women under various hormone exposures, tamoxifen therapy, and diet modifications, as well as in breast cancer patients. Results showed a significant positive correlation between estradiol and in vivo IL-1β levels, and a negative correlation with IL-1Ra in breast tissue. Tamoxifen or a dietary addition of 25 g flaxseed per day significantly increased IL-1Ra levels in the breast, findings that were confirmed in ex vivo cultures of breast biopsies.
Abrahamsson A, Morad V, Saarinen NM, et al. J Clin Endocrinol Metab, 2012. PMID 22930784
2012 / Ex vivo postprandial serum and in vitro cell culture study
Researchers examined the effects of walnut oil extracts, purified compounds (alpha-linolenic acid [ALA] and beta-sitosterol), and postprandial serum from individuals fed walnut components on breast cancer cells. Walnut oil extracts, ALA, and beta-sitosterol decreased the proliferation of MCF-7 cells and activated FXR more than other tested nuclear receptors. In TM2H mouse cells, ALA altered PPAR, LXR, and FXR target gene expression. Application of serum from individuals fed walnut components to MCF-7 cells showed a correlation between body mass index and in vitro breast cancer cell proliferation.
Vanden Heuvel JP, Belda BJ, Hannon DB, et al. Nutr Cancer, 2012. PMID 23061909
2012 / Randomized controlled trial
A randomized controlled trial evaluated 30 g daily resistant starch versus placebo for up to four years in 918 individuals with Lynch syndrome. Over a median follow-up of 52.7 months, 53 participants developed primary colorectal cancers. Intention-to-treat analysis showed no significant effect of resistant starch on time to first colorectal cancer (HR 1.40; 95% CI: 0.78-2.56; p = 0.26) or overall incidence rate (IRR 1.15; 95% CI: 0.66-2.00; p = 0.61).
Mathers JC, Movahedi M, Macrae F, et al. Lancet Oncol, 2012. PMID 23140761
2012 / Randomized, double-blind, placebo-controlled trial
The Physicians' Health Study II evaluated whether a daily multivitamin compared with placebo reduces cancer risk among 14,641 male US physicians followed for a median of 11.2 years. Men taking a daily multivitamin had a statistically significant reduction in total cancer incidence (17.0 vs 18.3 events per 1000 person-years; HR, 0.92; 95% CI, 0.86-0.998; P=.04). No significant effects were observed for prostate cancer (HR, 0.98; P=.76), colorectal cancer (HR, 0.89; P=.39), other site-specific cancers, or cancer mortality (HR, 0.88; 95% CI, 0.77-1.01; P=.07). A reduction in total cancer was seen among men with a baseline history of cancer (HR, 0.73; 95% CI, 0.56-0.96; P=.02), which did not differ significantly from men without baseline cancer (P for interaction = .07).
Gaziano JM, Sesso HD, Christen WG, et al. JAMA, 2012. PMID 23162860